Fig. 4From: Endoscopic central airway recanalization to enable first line pembrolizumab treatment in a PD-L1 strongly positive non-small cell lung cancer: a case reportChest CT scan performed before (Part a), and 16 weeks after immunotherapy (Part b) showed a reduction in tumor size (white arrow) without sign of lung infectionBack to article page